This is therefore a contrasting of the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation in Fate Therapeutics Inc. (NASDAQ:FATE) and KemPharm Inc. (NASDAQ:KMPH). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 represents Fate Therapeutics Inc. (NASDAQ:FATE) and KemPharm Inc. (NASDAQ:KMPH)s net margins, return on equity and return on assets.
Volatility & Risk
A 1.62 beta indicates that Fate Therapeutics Inc. is 62.00% more volatile compared to S&P 500. Competitively, KemPharm Inc.s beta is 1.33 which is 33.00% more volatile than S&P 500.
Liquidity
Fate Therapeutics Inc.s Current Ratio is 6.4 while its Quick Ratio is 6.4. On the competitive side is, KemPharm Inc. which has a 1 Current Ratio and a 1 Quick Ratio. Fate Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to KemPharm Inc.
Analyst Ratings
The next table highlights the delivered recommendations and ratings for Fate Therapeutics Inc. and KemPharm Inc.
Fate Therapeutics Inc. has a 30.49% upside potential and a consensus price target of $23.75. Meanwhile, KemPharm Inc.s average price target is $1.05, while its potential upside is 28.83%. Based on the analysts view we can conclude, Fate Therapeutics Inc. is looking more favorable than KemPharm Inc.
Institutional and Insider Ownership
Institutional investors owned 98.8% of Fate Therapeutics Inc. shares and 33.5% of KemPharm Inc. shares. Fate Therapeutics Inc.s share owned by insiders are 0.9%. Comparatively, KemPharm Inc. has 0.5% of its share owned by insiders.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Fate Therapeutics Inc. had bullish trend while KemPharm Inc. had bearish trend.
Summary
On 8 of the 9 factors Fate Therapeutics Inc. beats KemPharm Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companys immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Here is the original post:
Fate Therapeutics Inc. (FATE) and KemPharm Inc. (NASDAQ:KMPH) Comparison side by side - The EN Herald
- White Blood Cells (WBCs) - Definition, Function, and Ranges - August 22nd, 2022
- Cancer requires more tutoring, with Meyer continuing to Teaching Cancer a lesson - News - vintontoday.com - January 20th, 2021
- Huntington's Disease Alters Human Development in the Fetal... : Neurology Today - LWW Journals - August 26th, 2020
- Science Becomes A Dividing Issue In Year Of Election And Pandemic - Iowa Public Radio - April 29th, 2020
- Lost Smell and Taste Hint COVID-19 Can Target the Nervous System - The Scientist - March 29th, 2020
- Stem Cell Treatment for Cartilage Regeneration ... - March 14th, 2020
- UI doctors discover new genetic mutation that causes fatal heart arrhythmias - UI The Daily Iowan - February 22nd, 2020
- What will the US look like in 2030? | Articles - telegraphherald.com - February 9th, 2020
- Red Shamrock: Fight never over, even when kids beat cancer - Iowa City Press-Citizen - January 9th, 2020
- Biden Exaggerates Science on Burn Pits and Brain Cancer - FactCheck.org - December 22nd, 2019
- Common Prostate Drug May Slow Progression of Parkinson, Researchers Say - AJMC.com Managed Markets Network - September 23rd, 2019
- Contrasting of Cellular Biomedicine Group Inc. (CBMG) and KemPharm Inc. (NASDAQ:KMPH) - The EN Herald - September 23rd, 2019
- Our Team - Neural Stem Cell Institute, Rensselaer NY - April 12th, 2019
- Cultured meat - Wikipedia - January 20th, 2019
- Stem Cell - Joint Preservation Institute of Iowa - August 9th, 2018
- Stem cell therapy and healing meniscus damage - Dr. Marc ... - July 29th, 2018
- The importance of stem cell numbers in stem cell therapy ... - July 17th, 2018
- Blood and Marrow Transplant Program | University of Iowa ... - July 15th, 2018
- Regenexx Des Moines | Iowa's Regenexx Provider - October 15th, 2017
- Stem Cells - Joint Preservation Institute of Iowa - September 3rd, 2017
- US record holder for most time in space Peggy Whitson returns to Earth after 288-day mission - Pulse Headlines - September 3rd, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Iowa Public Radio - September 3rd, 2017
- Stem cells: JP2MRI, CET discover safer, more ethical biotechnology - Sioux City Catholic Globe - July 2nd, 2017
- Mesenchymal Stem Cell Therapy - Cedar Rapids, Iowa City ... - November 10th, 2016
- Des Moines, Iowa Stem Cell Transplants, Clive, Grimes ... - November 8th, 2016
- Stem Cell Research | Environmental Health and Safety - October 21st, 2016
- Molecular imaging of stem cells | StemBook - August 23rd, 2016
- Telomere elongation in induced pluripotent stem cells from ... - October 19th, 2015
- Hair Loss Cure One Step Closer To Reality; Scientists Grow ... - October 19th, 2015
- Are Cancer Stem Cells the Key to Discovering a Cure ... - October 6th, 2015
- University of Iowa Stem Cell Group - October 6th, 2015
- Stem Cells + HA New Injection for Knees?; Fracture Repair ... - September 27th, 2015
- Des Moines IA Resources - Stem Cells: Get Facts on ... - July 2nd, 2015
- Stem Cell Banking Market in India 2015-2019 - Sioux City ... - June 10th, 2015
- How Do Stem Cells Help Cure Parkinson's Disease? | eHow - March 18th, 2015
- UI researchers tout diabetes development - January 29th, 2015
- stem cell research | LVATUG blog - December 16th, 2014
- NYSCF and the CMTA enter collaboration to advance neuropathies research - December 11th, 2014
- stem cell - FierceBiotech - Biotech Industry, Biotech News ... - December 2nd, 2014
- IOWA AND STEM CELLS: Braley/Ernst Race has National Impact - October 21st, 2014
- Genesis launches new Neuroscience Institute - October 1st, 2014
- Cedar Rapids IA Resources - Stem Cells: Get Facts on Uses ... - September 24th, 2014
- Institute has raised $400K in donations - September 20th, 2014
- Iowa City-area institute gets $400,000 from Ice Bucket ... - September 13th, 2014
- ISU Bioethics Outreach--Stem Cells - Iowa State University - September 13th, 2014
- Ames IA Stem Cell Treatment | Ames Iowa Cancer Stem Cell ... - September 5th, 2014
- Iowa opens new debate over use of stem cells - September 1st, 2014
- Catholics asked to NOT donate to the ALS Association - August 29th, 2014
- Catholic Church At Odds With Ice Bucket Challenge - August 26th, 2014
- Why some are wary about doing ALS challenge - August 23rd, 2014
- Archdiocese of St. Louis warning about the, Ice Bucket Challenge - August 23rd, 2014
- Iowa Stem Cell Therapy | Stem Cell Treatments - August 22nd, 2014
- Ohio diocese discourages ice bucket challenge - August 22nd, 2014